These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30198595)

  • 1. Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.
    Johnson TN; Cleary Y; Parrott N; Reigner B; Smith JR; Toovey S
    Br J Clin Pharmacol; 2019 Jan; 85(1):100-113. PubMed ID: 30198595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.
    Schlagenhauf P; Adamcova M; Regep L; Schaerer MT; Bansod S; Rhein HG
    Malar J; 2011 Oct; 10():292. PubMed ID: 21981927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
    Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
    Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon.
    Ramharter M; Kurth FM; Bélard S; Bouyou-Akotet MK; Mamfoumbi MM; Agnandji ST; Missinou MA; Adegnika AA; Issifou S; Cambon N; Heidecker JL; Kombila M; Kremsner PG
    J Antimicrob Chemother; 2007 Nov; 60(5):1091-6. PubMed ID: 17884832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
    Simpson JA; Price R; ter Kuile F; Teja-Isavatharm P; Nosten F; Chongsuphajaisiddhi T; Looareesuwan S; Aarons L; White NJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):472-84. PubMed ID: 10579474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.
    Gutman J; Green M; Durand S; Rojas OV; Ganguly B; Quezada WM; Utz GC; Slutsker L; Ruebush TK; Bacon DJ
    Malar J; 2009 Apr; 8():58. PubMed ID: 19358697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
    Reuter SE; Upton RN; Evans AM; Navaratnam V; Olliaro PL
    J Antimicrob Chemother; 2015 Mar; 70(3):868-76. PubMed ID: 25377567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
    Guidi M; Mercier T; Aouri M; Decosterd LA; Csajka C; Ogutu B; Carn G; Kiechel JR
    Malar J; 2019 Apr; 18(1):139. PubMed ID: 30999915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border.
    Hoglund RM; Ruengweerayut R; Na-Bangchang K
    Malar J; 2018 Sep; 17(1):322. PubMed ID: 30176888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
    Olafuyi O; Coleman M; Badhan RKS
    Eur J Pharm Sci; 2017 Aug; 106():20-33. PubMed ID: 28546104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mefloquine concentration profiles during prophylactic dose regimens.
    Kollaritsch H; Karbwang J; Wiedermann G; Mikolasek A; Na-Bangchang K; Wernsdorfer WH
    Wien Klin Wochenschr; 2000 May; 112(10):441-7. PubMed ID: 10890135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
    Staehli Hodel EM; Guidi M; Zanolari B; Mercier T; Duong S; Kabanywanyi AM; Ariey F; Buclin T; Beck HP; Decosterd LA; Olliaro P; Genton B; Csajka C
    Malar J; 2013 Jul; 12():235. PubMed ID: 23841950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.
    Jullien V; Valecha N; Srivastava B; Sharma B; Kiechel JR
    Malar J; 2014 May; 13():187. PubMed ID: 24886117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
    Krudsood S; Looareesuwan S; Tangpukdee N; Wilairatana P; Phumratanaprapin W; Leowattana W; Chalermrut K; Ramanathan S; Navaratnam V; Olliaro P; Vaillant M; Kiechel JR; Taylor WR
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3730-7. PubMed ID: 20547795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.
    Charles BG; Blomgren A; Nasveld PE; Kitchener SJ; Jensen A; Gregory RM; Robertson B; Harris IE; Reid MP; Edstein MD
    Eur J Clin Pharmacol; 2007 Mar; 63(3):271-8. PubMed ID: 17216435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric Patients.
    Lin W; Heimbach T; Jain JP; Awasthi R; Hamed K; Sunkara G; He H
    J Pharm Sci; 2016 Oct; 105(10):3205-3213. PubMed ID: 27506269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.
    Valea I; Tinto H; Traore-Coulibaly M; Toe LC; Lindegardh N; Tarning J; Van Geertruyden JP; D'Alessandro U; Davies GR; Ward SA
    J Antimicrob Chemother; 2014 Sep; 69(9):2499-507. PubMed ID: 24891429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
    Smithuis F; Kyaw MK; Phe O; Win T; Aung PP; Oo AP; Naing AL; Nyo MY; Myint NZ; Imwong M; Ashley E; Lee SJ; White NJ
    Lancet Infect Dis; 2010 Oct; 10(10):673-81. PubMed ID: 20832366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.